Phase Ib/II Study of CPX-351 Plus Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

被引：0
|
作者：
Bharathi, Vanthana [1 ]
Bataller, Alex [2 ]
Bazinet, Alexandre [1 ]
Borthakur, Gautam [3 ]
Jabbour, Elias [1 ]
Daver, Naval [4 ]
Short, Nicholas J. [1 ]
Takahashi, Koichi [1 ]
Issa, Ghayas C. [1 ]
Dinardo, Courtney D. [1 ]
Pemmaraju, Naveen [1 ]
Jain, Nitin [1 ]
Montalban-Bravo, Guillermo [1 ]
Wierda, William G. [2 ]
Ravandi, Farhad [1 ]
Kantarjian, Hagop M. [1 ]
Kadia, Tapan M. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Sect Mol Hematol & Therapy, Houston, TX USA
[4] MD Anderson Canc Ctr, Houston, TX USA
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-209157
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：4272 / 4274
页数：3
相关论文
共 50 条
  • [41] IN VIVO RAT METABOLISM OF AN ACUTE MYELOID LEUKEMIA (AML) DRUG CPX-351 (CYTARABINE: DAUNORUBICIN) LIPOSOME INJECTION
    Kim-Kang, Heasook
    Yi, Yijun
    Wang, Peter L.
    Tardi, Paul
    Xie, Sherwin
    Mayer, Lawrence
    DRUG METABOLISM REVIEWS, 2015, 47 : 187 - 187
  • [42] Phase IB/II Study of Lirilumab in Combination with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML)
    Daver, Naval
    Garcia-Manero, Guillermo
    Basu, Sreyashi
    Cortes, Jorge E.
    Ravandi, Farhad
    Jabbour, Elias J.
    Pierce, Sherry
    Ning, Jing
    Konopleva, Marina
    Andreeff, Michael
    Kornblau, Steven M.
    Borthakur, Gautam
    Pemmaraju, Naveen
    Bueso-Ramos, Carlos E.
    Lopez, Juliana Elisa Hidalgo
    Blando, Jorge
    Allison, James
    Kantarjian, Hagop M.
    Sharma, Padmanee
    BLOOD, 2016, 128 (22)
  • [43] PHASE IB/II STUDY OF NIVOLUMAB IN COMBINATION WITH AZACYTIDINE (AZA) IN PATIENTS (PTS) WITH RELAPSED ACUTE MYELOID LEUKEMIA (AML)
    Daver, N.
    Basu, S.
    Garcia-Manero, G.
    Cortes, J.
    Ravandi, F.
    Jabbour, E.
    Pemmaraju, N.
    Hendrickson, S.
    Gordon, T.
    Brandt, M.
    Pierce, S.
    Matthews, J.
    Kornblau, S.
    Flores, W.
    Konopleva, M.
    Kantarjian, H.
    Sharma, P.
    HAEMATOLOGICA, 2017, 102 : 176 - 177
  • [44] A Phase I Study of Pevonedistat, Azacitidine and Venetoclax for Patients with Relapsed/Refractory Acute Myelogenous Leukemia (AML)
    Murthy, Guru Subramanian Guru
    Kaufmann, Scott H.
    Szabo, Aniko
    Harrington, Alexandra M.
    Michaelis, Laura C.
    Abedin, Sameem
    Carlson, Karen
    Runaas, Lyndsey
    Longo, Walter L.
    Hinman, Alexander
    Maldonado-Schmidt, Sonia
    Thomas, Althea
    Baim, Arielle
    Litzow, Mark R.
    Atallah, Ehab L.
    BLOOD, 2021, 138
  • [45] A phase II study of bisantrene in patients with relapsed/refractory acute myeloid leukemia
    Canaani, Jonathan
    Danylesko, Ivetta
    Shemtov, Noga
    Zlotnick, Maya
    Lozinsky, Kira
    Benjamini, Ohad
    Yerushalmi, Ronit
    Nagar, Meital
    Dor, Chen
    Shimoni, Avichai
    Avigdor, Abraham
    Nagler, Arnon
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2021, 106 (02) : 260 - 266
  • [46] Application of a Phenotype-Based Predictive Analytic in a Phase Ib Study of Selinexor and Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia
    Ball, Somedeb
    Byrne, Michael T.
    Fischer, Melissa A.
    Awan, Farrukh T.
    Tomlinson, Ben K.
    Stopczynski, Tess
    Patil, Lokesh
    Gu, Christine J.
    Leonardi, Chris
    Walsh, Katherine J.
    Dan Ayers, Gregory
    Kishtagari, Ashwin
    Fedorov, Kateryna
    Lacher, Markus D.
    Wagner, Joseph
    Mohan, Sanjay R.
    Savona, Michael R.
    BLOOD, 2024, 144 : 6012 - 6013
  • [47] A Phase II Study of Bisantrene in Patients with Relapsed/Refractory Acute Myeloid Leukemia
    Canaani, Jonathan
    Danilesko, Ivetta
    Shem-Tov, Noga
    Zlotnick, Maya
    Lozinsky, Kira
    Benjamini, Ohad
    Yerushalmi, Ronit
    Nagar, Meital
    Dor, Chen
    Shimoni, Avichai
    Avigdor, Abraham
    Nagler, Arnon
    BLOOD, 2020, 136
  • [48] Real World Survival Outcomes of CPX-351 Versus Venetoclax and Azacitadine for Initial Therapy in Adult Acute Myeloid Leukemia
    Matthews, Andrew
    Perl, Alexander E.
    Luger, Selina M.
    Babushok, Daria V.
    Frey, Noelle V.
    Gill, Saar
    Hexner, Elizabeth O.
    Martin, Mary Ellen
    McCurdy, Shannon R.
    Porter, David L.
    Stadtmauer, Edward A.
    Loren, Alison W.
    Paralkar, Vikram R.
    Maillard, Ivan
    Margolis, David
    Pratz, Keith W.
    BLOOD, 2021, 138
  • [49] Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent
    Steinauer, Nickolas
    McCullough, Kristen
    Al-Kali, Aref
    Alkhateeb, Hassan B.
    Begna, Kebede H.
    Mangaonkar, Abhishek A.
    Saliba, Antoine N.
    Torghabeh, Mehrdad
    Litzow, Mark R.
    Hogan, William J.
    Shah, Mithun
    Patnaik, Mrinal M.
    Pardanani, Animesh
    Badar, Talha
    Murthy, Hemant
    Foran, James
    Yi, Cecilia Arana
    Tefferi, Ayalew
    Gangat, Naseema
    HAEMATOLOGICA, 2024, 109 (08) : 2706 - 2710
  • [50] Venetoclax Plus Hypomethylating Agents for Relapsed/Refractory Acute Myeloid Leukemia (AML) Is Safe and Manageable in the Outpatient Setting
    Nanni, Jacopo
    Papayannidis, Cristina
    Cristiano, Gianluca
    Marconi, Giovanni
    Sartor, Chiara
    Parisi, Sarah
    Ottaviani, Emanuela
    Baldini, Lorenza
    Testoni, Nicoletta
    Baldazzi, Carmen
    Ricci, Paolo
    Bezzi, Chiara Di Giovanni
    Abd-alatif, Rania
    Paolini, Stefania
    Cavo, Michele
    Curti, Antonio
    BLOOD, 2020, 136
12345